Zocef-CV 500 Tablet is a combination antibiotic formulation containing Cefuroxime 500 mg and Clavulanic Acid 125 mg, designed to treat a wide range of bacterial infections. Cefuroxime, a second-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effectively targeting both Gram-positive and Gram-negative organisms. Clavulanic Acid acts as a beta-lactamase inhibitor, preventing the enzymatic degradation of Cefuroxime by beta-lactamase-producing bacteria, thereby enhancing its efficacy against resistant strains. Zocef-CV 500 is indicated for the management of respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, and sinusitis caused by susceptible pathogens. The combination is particularly useful in infections where beta-lactamase-producing bacteria are suspected or confirmed. The tablet should be administered orally, with dosage and duration determined by the severity and type of infection, as well as patient-specific factors such as age and renal function. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort, while hypersensitivity reactions are rare but possible. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Zocef-CV 500 Tablet should be used under medical supervision to ensure appropriate use and to minimize the risk of resistance development.